Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress.
about
Which is safer source plasma for manufacturing in China: apheresis plasma or recovered plasma?Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infectionsHepatitis E: an old infection with new implications.Blood donor selection in European Union directives: room for improvement.The Prevention of Periprosthetic Joint Infections.Description of 15 DNA-positive and antibody-negative "window-period" blood donations identified during prospective screening for Babesia microti.Will pathogen reduction of blood components harm more people than it helps in developed countries?Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors.On risk appraisal of behaviour.Research on the human virome: where are we and what is next.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety.First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia.Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light.
P2860
Q33432155-A97FA642-286F-4E7D-B29D-B75AD9CC123CQ33852543-D66BE0DE-86EC-490D-B0C6-A223A13039A4Q34079348-924F4D8C-EF65-411E-8689-5EF7472503CDQ35049128-5FCBF6E6-CFA7-4DB8-8285-EFDA64893A4CQ36660746-D027D85C-EDDC-430E-B380-BBE6BD8A0C22Q37580823-B9BCDA0A-1B09-489B-BB61-A061292750E1Q38814836-B899E891-6FAA-4614-A74E-E41E378C9F98Q38831832-A19DE940-4C7F-47A6-B512-732803002FD0Q40324501-1894477E-BBC2-4F20-AE32-5E71B66453EFQ40967079-982DD2A7-0B6E-41AA-ACE8-463935B4377EQ42367943-52A6F1ED-3261-423B-8567-D4C02FB09039Q42543729-D9552358-6FA5-41B9-99B4-D41D7824511DQ45869919-932BFD6F-11D2-4EC7-8AA8-0ABF68632948Q50237622-F5335F60-78EB-41AD-8896-B4F0DC5C9744Q52641763-62FB48D5-2E33-4477-8A5E-5AE5CE169CABQ54200365-D89EFE43-8DB7-4D03-9245-F17730A388E6
P2860
Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Transfusion-transmitted emergi ...... rs of challenges and progress.
@en
Transfusion-transmitted emergi ...... rs of challenges and progress.
@nl
type
label
Transfusion-transmitted emergi ...... rs of challenges and progress.
@en
Transfusion-transmitted emergi ...... rs of challenges and progress.
@nl
prefLabel
Transfusion-transmitted emergi ...... rs of challenges and progress.
@en
Transfusion-transmitted emergi ...... rs of challenges and progress.
@nl
P2860
P356
P1433
P1476
Transfusion-transmitted emergi ...... rs of challenges and progress.
@en
P2093
AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup
Roger Y Dodd
P2860
P304
P356
10.1111/TRF.12371
P433
P577
2013-08-09T00:00:00Z